Effect of maternal obesity on the expression level of P-glycoprotein in human placenta

doi:10.3877/cma.j.issn.1673-5250.2015.01.003

Objective

To evaluate the effect of maternal obesity on the expression level of P-glycoprotein in human placenta, and to provide a theoretical basis for individualized dosage regimen of digoxin prenatal intervention for fetal heart failure.

Methods

A total of 25 puerperants with normal and full-term pregnancy in West China Second University Hospital, Sichuan University from March to June 2013 were chosen as study subjects.In accordance with the pre-pregnancy body mass index(BMI), they were divided into obesity group(n=10, BMI≥27.9 kg/m²)and control group(n=15, 18.5 kg/m²≤BMI<23.9 kg/m²). Placentas were collected at birth.The relative expression levels of ABCB1 mRNA and P-glycoprotein in the placenta were determined by the methods of real-time polymerase chain reaction (RT-PCR) and Western blotting, and the data were analyzed statistically.The study protocol was approved by the Ethical Review Board of Investigation in Human Being of West China Second University Hospital, Sichuan University.Informed consent was obtained from each participant.

Results

①Both the pre-pregnancy BMI and BMI at birth of obesity group were significantly higher than those of control group(t=20.88, 11.66; P<0.001); but there were no significant differences between two groups in maternal age, gestational age, gravidity, parity, constituent ratio of neonatal sex, neonatal weight, neonatal body length and placental weight(P>0.05). ②The relative expression levels of ABCB1 mRNA and P-glycoprotein in placenta of obesity group were both significantly lower than those of control group(t=-2.146, P=0.043; t=-3.862, P=0.005).

Conclusions

The digoxin concentration in fetal compartment might increase in obese mothers during pregnancy, suggesting that lower dosage of digoxin should be given to obese pregnant women when given prenatal intervention for fetal heart failure.

Key words: P-glycoprotein, Obesity, Body mass index, Placenta

表1 两组产妇及其新生儿一般临床资料比较(±s)

Table 1 Comparison of maternal and neonatal general clinical data between two groups(±s)

组别	例数	孕前BMI (kg/m²)	产时BMI (kg/m²)	母亲年龄(岁)	孕龄(周)	孕次(次)	产次(次)	新生儿性别构成比[n(%)]		新生儿体质量(g)	新生儿身长(cm)	胎盘重量(g)
组别	例数	孕前BMI (kg/m²)	产时BMI (kg/m²)	母亲年龄(岁)	孕龄(周)	孕次(次)	产次(次)	男	女	新生儿体质量(g)	新生儿身长(cm)	胎盘重量(g)
肥胖组	10	29.1±1.1	35.2±2.1	31.4±2.9	40.1±1.2	1.9±1.0	1.1±0.3	50.0	50.0	3 544.0±256.7	50.8±0.9	576.4±68.9
正常组	15	20.4±0.9	26.6±1.6	31.0±4.1	39.5±0.8	2.8±1.6	1.3±0.5	66.7	33.3	3 454.0±250.5	50.3±1.0	568.4±85.2
t值/χ²值	?	20.88	11.66	0.27	1.58	－1.57	－1.33	0.69	0.87	1.38	0.26	?
P值	?	<0.001	<0.001	0.792	0.128	0.130	0.196	0.405	0.392	0.180	0.798	?

表1 两组产妇及其新生儿一般临床资料比较(±s)

Table 1 Comparison of maternal and neonatal general clinical data between two groups(±s)

组别	例数	孕前BMI (kg/m²)	产时BMI (kg/m²)	母亲年龄(岁)	孕龄(周)	孕次(次)	产次(次)	新生儿性别构成比[n(%)]		新生儿体质量(g)	新生儿身长(cm)	胎盘重量(g)
组别	例数	孕前BMI (kg/m²)	产时BMI (kg/m²)	母亲年龄(岁)	孕龄(周)	孕次(次)	产次(次)	男	女	新生儿体质量(g)	新生儿身长(cm)	胎盘重量(g)
肥胖组	10	29.1±1.1	35.2±2.1	31.4±2.9	40.1±1.2	1.9±1.0	1.1±0.3	50.0	50.0	3 544.0±256.7	50.8±0.9	576.4±68.9
正常组	15	20.4±0.9	26.6±1.6	31.0±4.1	39.5±0.8	2.8±1.6	1.3±0.5	66.7	33.3	3 454.0±250.5	50.3±1.0	568.4±85.2
t值/χ²值	?	20.88	11.66	0.27	1.58	－1.57	－1.33	0.69	0.87	1.38	0.26	?
P值	?	<0.001	<0.001	0.792	0.128	0.130	0.196	0.405	0.392	0.180	0.798	?

图1 两组胎盘组织中ABCB1 mRNA相对表达量比较

Figure 1 Comparison of relative expressions of placental ABCB1 mRNA between two groups

图2 两组胎盘组织中P-糖蛋白Western blotting结果

Figure 2 Western blotting results of placental P-glycoprotein of two groups

图3 两组胎盘组织中P-糖蛋白相对表达量比较

Figure 3 Comparison of relative expressions of placental P-glycoprotein between two groups

表2 两组产妇胎盘组织中ABCB1 mRNA及P-糖蛋白相对表达量比较(±s)

Table 2 Comparison of relative expression levels of ABCB1 mRNA and P-glycoprotein in placentas between two groups(±s)

分组	例数	mRNA相对表达量	蛋白相对表达量
肥胖组	10	20.7± 6.0	0.2±0.4
正常组	15	52.2±11.2	0.5±0.5
t值	?	－2.146	－3.862
P值	?	0.043	0.005

表2 两组产妇胎盘组织中ABCB1 mRNA及P-糖蛋白相对表达量比较(±s)

Table 2 Comparison of relative expression levels of ABCB1 mRNA and P-glycoprotein in placentas between two groups(±s)

分组	例数	mRNA相对表达量	蛋白相对表达量
肥胖组	10	20.7± 6.0	0.2±0.4
正常组	15	52.2±11.2	0.5±0.5
t值	?	－2.146	－3.862
P值	?	0.043	0.005

[1]	Andrade SE，Gurwitz JH，Davis RL，et al. Prescription drug use in pregnancy[J]. Am J Obstet Gynecol，2004，191(2)：398–407.
[2]	Ceckova-Novotna M，Pavek P，Staud F. P-glycoprotein in the placenta: expression, localization，regulation and function[J]．Reprod Toxicol，2006，22(3)：400–410.
[3]	Holcberg G，Sapir O，Tsadkin M，et al.Lack of interaction of digoxin and P-glycoprotein inhibitors，quinidine and verapamil in human placenta in vitro[J]. Eur J Obstet Gynecol Reprod Biol，2003，109(2)：133–137.
[4]	Wang C，Li H，Zhou K，et al. Sodium tanshinone ⅡA sulfonate and sodium danshensu open the placental barrier through down-regulation of placental P-glycoprotein in mice: implications in the transplacental digoxin treatment for fetal heart failure[J]．Int J Cardiol，2014，176(3)：1331–1333.
[5]	Anger GJ，Cressman AM，Piquette-Miller M. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes[J]．PLoS One，2012，7(4)：e35027.
[6]	Soo PS，Hiscock J，Botting KJ，et al.Maternal undernutrition reduces P-glycoprotein in guinea pig placenta and developing brain in late gestation[J]．Reprod Toxicol，2012，33(3)：374–381.
[7]	Lumeng CN，Bodzin JL，Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization[J]．J Clin Invest，2007，117(1)：175–184.
[8]	Challier JC，Basu S，Bintein T, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta[J]. Placenta，2008，29(3)：274–281.
[9]	Ramsay JE，Ferrell WR，Crawford L，et al. Maternal obesity is associated with dysregulation of metabolic，vascular，and inflammatory pathways[J]．J Clin Endocrinol Metab，2002，87(9)：4231–4237.
[10]	Evseenko DA，Paxton JW，Keelan JA.Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors[J]．Drug Metab Dispos，2007，35(4)：595–601.
[11]	Petrovic V，Piquette-Miller M．Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats[J]. Drug Metab Dispos，2010，38(10)：1760–1766.
[12]	Zatelli MC，Molè D，Tagliati F，et al. Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB[J]. Cell Oncol，2009，31(6)：457–465.
[13]	Cygalova L，Ceckova M，Pavek P，et al. Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat[J]. Toxicol Lett, 2008, 178(3)：176–180.
[14]	Scotto KW.Transcriptional regulation of ABC drug transporters[J]. Oncogene, 2003，22(47)：7496–7511.
[15]	Sukhai M，Yong A，Pak A，et al.Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes[J]．Inflamm Res，2001，50(7)：362–370.
[16]	张洁，王方，许海燕，等．炎性因子与胰岛素抵抗[J]．世界华人消化杂志，2006，14(32): 3121–3125.
[17]	Liu H，Yang H，Wang D，et al.Insulin regulates P-glycoprotein in rat brain microvessel endothelial cells via an insulin receptor-mediated PKC/NF-kappa B pathway but not a PI3K/Akt pathway[J]．Eur J Pharmacol，2009，602(2-3)：277–282.
[18]	Zhou SF.Structure，function and regulation of P-glycoprotein and its clinical relevance in drug disposition[J]．Xenobiotica，2008，38(7-8)：802–832.
[19]	Gulati A，Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy[J]．J Pharm Sci，2009，98(7)：2317–2335.
[20]	Zhou K，Zhou R，Zhu Q，et al.Evaluation of therapeutic effect and cytokine change during transplacental Digoxin treatment for fetal heart failure associated with fetal tachycardia，a case-control study[J]．Int J Cardiol，2013，169(4)：e62–e64.
[21]	Zhou KY，Hua YM，Zhu Q. Transplacental digoxin therapy for fetal atrial flutter with hydrops fetalis[J]. World J Pediatr，2012，8(3)：275–277.
[22]	Lankas GR，Wise LD，Cartwright ME，et al. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice[J]．Reprod Toxicol，1998，12(4)：457–463.
[23]	Wang C，Xie L，Zhou K，et al.Increased risk for congenital heart defects in children carrying the ABCB1 Gene C3435T polymorphism and maternal periconceptional toxicants exposure[J]．PLoS One，2013，8(7)：e68807.

[1]	Jinmei He, Lixue Yin, Jing Tan, Wenjun Zhang, Rui Wang, Mei Ren, Mingjiao Liao. Evaluation of potential left ventricular systolic dysfunction in patients with type 2 diabetes mellitus using ultrasonic myocardial work technology[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(10): 1029-1035.
[2]	Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.
[3]	Kailun Ji, Shaolong Hao, Haitao Sun, Wei Han. New progress of gallstone formation mechanism after weight loss[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 100-103.
[4]	Damin Chen, Xiaogang Cao, Nengqi Cao. Effect of obesity on surgical treatment of gastric cancer patients[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 651-653.
[5]	Yu Song, Yang Zhao, Huijun Wang, Xinhua Liao. Relationship between preoperative BMI and postoperative complications and long-term survival in patients with resectable gastric cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 530-533.
[6]	Yunlin Li, Donghua Lou. Analysis on the influencing factors of the incidence and remission of non-alcoholic fatty liver disease in Binhai County[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 354-358.
[7]	Ke Meng, Yan Li, Jingshuang Yan, Bin Yan. Risk factors for prolonged gastric transit time in capsule endoscopy[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 671-675.
[8]	Wenxing Gao, Hao Liu, Wen Zhao, Dingchang Li, Peng Chen, Lujia Jin, Xianqiang Liu, Guanglong Dong. Chronic abdominal pain after bariatric surgery: causes and countermeasures[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 149-154.
[9]	Junrong Ma, Yanbin Ye. Nutritional management and weight regain after bariatric surgery: current situation and thoughts[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 165-172.
[10]	Xiaoxuan Fan, Na Wang, Lihua Zhu, Liang Wang. Research progress of obesity-related tumors[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 173-178.
[11]	Jinliang Li, Maojuan Zeng, Jinbao Zhong, Weiqiang He, Wenxin Lin. Effect of semaglutide on skin microcirculatory function in obese patients with type 2 diabetes mellitus[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 192-196.
[12]	Yuling Liu, Tingting Wang, Gaofeng Wu, Shujing Yu. Correlation between visceral fat area and novel inflammatory markers in healthy physical examination population[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 197-202.
[13]	Ao Liu, Jing Zhou, Yongbing Sun, Junya He, Xinbei Lin, Qi Qiao, Zhonglin Li, Jiancheng Zhang, Xiaoling Wu, Zhi Zou, Yangxi Hu, Xinguang Xiao, Xue Lv, Hao Li, Yongli Li. Progress of research in neuroimaging changes and cognitive function assessment after bariatric metabolic surgery[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 203-208.
[14]	Wuyao Qin, Wenhui Gao, Hao Cui, Jiwen Shang. Research progress of correlation between aldosterone and adipocytes[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 209-214.
[15]	Xiaomei Chen, Wenhui Chen, Wan'e Zhao, Jie Guo, Chao Su, Zhiju Fu, Wah Yang, Zhiyong Dong, Cunchuan Wang. Swallowable and self-absorbing novel intragastric balloon for mild obesity: a case report[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 215-217.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export